Citations

Clear

3138 citation(s) found for "Smith, AM".

Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans
Masselink, Leah E. , Erikson, Clese , Connell, Nathan T. , Castro, Laura M. De , Dent, Georgette A. , Marshall, Ariela L. , Naik, Rakhi P. , Nelson, Marquita , Rajasekhar, Anita, Sharma, Deva , Smith, Melody , Lee, Alfred Ian , Marshall, Ariela , Smith, Melody , O'Connell, Casey Lee

Mayo Clinic

Blood Advances | October 31, 2019 | Volume: 3 | Issue: 21 | Pages: 3278-3286

10.1182/bloodadvances.2019000569 | PMID 31698456 Get It

Key PointsClinical, research and mentorship experiences in hematology are positively associated with fellows' plans to pursue hematology-only careers.
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis
Gelbard, Alexander , Anderson, Catherine , Berry, Lynne D. , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fernandes‐Taylor, Sara , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Guardiani, Elizabeth , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Huang, Li‐Ching , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Mannion, Kyle , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , Netterville, James L. , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Rohde, Sarah L. , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Chen, Sheau-Chiann , Ongkasuwan, Julian , Cohen, Seth M , Hoffman, Henry T , Richardson, Brent E , Gelbard, Alexander , Weissbrod, Philip A , Bock, Jonathan M. , Clary, Matthew S. , Hillel, Alexander T. , Lott, David G. , Weinberger, Paul , Amin, Milan R

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 31, 2019 | Volume: 146 | Issue: 1 | Pages: 20

10.1001/jamaoto.2019.3022 | PMID 31670805 Get It

Tau deposition in young adults with drug‐resistant focal epilepsy
Smith, Kelsey M. , Blessing, Melissa M. , Parisi, Joseph E. , Mandrekar, Jay , Cascino, Gregory D. , Smith, Kelsey M , Britton, Jeffrey W.

Mayo Clinic

Epilepsia | October 30, 2019 | Volume: 60 | Issue: 12 | Pages: 2398-2403

10.1111/epi.16375 | PMID 31663115 Get It

AbstractObjectiveTo evaluate the presence of tau deposition and pathologic features of chronic traumatic encephalopathy (CTE) in young adult patients treated with focal cortical resections for drug‐resistant epilepsy.MethodsSixty consecutive patients who had undergone surgical treatment for drug‐resistant focal epilepsy between 18 and 45 years of age were identified (2010‐2017). Medical records were reviewed to determine clinical factors, including history of head trauma, age at seizure onset, age at surgical resection, seizure type(s) and frequency, imaging findings, and surgical outcome. All formalin‐fixed, paraffin‐embedded blocks from the surgical specimens from each subject were sectioned and stained with hematoxylin and eosin and antibodies to tau (Thermo Fisher Scientific Clone AT8), and examined blindly for tau pathology, including lesions characteristic of CTE.ResultsThe median age at resection was 29.5 years (range = 19‐45). A history of head trauma was reported in 19 patients. Although none of the patients had pathological findings characteristic of CTE, 23 patients (38%) demonstrated tau‐immunoreactive lesions, including neurites, neurofibrillary pretangles, neurofibrillary tangles, subpial tau, and/or glial tau. In 4 of the 23 patients (7% of the cohort; 17% of those with tau pathology), substantial tau burden was identified. Three of these 4 patients had no significant history of head trauma; 1 patient had multiple sports‐related concussions. No specific clinical factors correlated with the presence of tau pathology.SignificanceTau‐immunoreactive lesions were found in 38% of 60 patients who underwent a focal cortical resection for drug‐resistant focal epilepsy. Diagnostic features of CTE were not detected in any patient; however, the pathological evaluation for CTE was limited to a surgical specimen. The prominent and excessive tau deposition in 23 patients (38%) is abnormal in this age group and warrants further investigation.
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Rimawi, Mothaffar F. , Rexer, Brent N. , Forero, Andres , Wolff, Antonio C. , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Jiralerspong, Sao , Pavlick, Anne C. , Veeraraghavan, Jamunarani , Angelis, Carmine De , Osborne, C. Kent , Wang, Tao , Wolff, Antonio C , Schiff, Rachel , Hilsenbeck, Susan Galloway , Rimawi, Mothaffar , De Angelis, Carmine , Niravath, Polly Ann , Wang, Tao , Goetz, Matthew P. , Gutiérrez, Carolina , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | October 29, 2019 | Volume: 26 | Issue: 4 | Pages: 821-827

10.1158/1078-0432.ccr-19-0851 | PMID 31662331 Get It

Abstract Purpose: Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR. Patients and Methods: TBCRC023 (NCT00999804) is a randomized phase II trial combining a Simon phase II design in the experimental arm with a pick-the-winner design, not powered for direct comparison. Women with HER2-positive breast tumors measuring ≥2 cm (median = 5 cm) were randomized in a 1:2 ratio to 12 versus 24 weeks of lapatinib and trastuzumab. Letrozole (along with ovarian suppression if premenopausal) was administered in patients whose tumors were also estrogen receptor (ER) positive. All evaluable patients were assessed for in-breast pCR. Results: Ninety-seven patients were enrolled (33 in 12-week arm and 64 in 24-week arm), of whom 94 were evaluable. Median age was 51 years, and 55% were postmenopausal. Median tumor size was 5 cm, and 65% were ER-positive. The rate of pCR in the 24-week arm was 28% and numerically superior to the 12-week arm (12%). This was driven by increased pCR in the ER-positive subgroup (33% vs. 9%). Study treatment was well tolerated, with grade 1–2 diarrhea and acneiform rash being the most common toxicities. Conclusions: Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. If validated, this approach may help identify patients who may benefit from deescalation of therapy.
Kidney transplant practice patterns and outcome benchmarks over 30 years: The 2018 report of the NAPRTCS
Chua, Annabelle N. , Cramer, Carl H. , Martz, Karen, Smith, Jodi M. , Blydt‐Hansen, Tom , Neu, Alicia M. , Dharnidharka, Vikas R. , investigators, the NAPRTCS, Cramer, Carl, Blydt-Hansen, Tom , Dharnidharka, Vikas R , Smith, Jodi , Moudgil, Asha , investigators, the NAPRTCS

Mayo Clinic

Pediatric Transplantation | October 28, 2019 | Volume: 23 | Issue: 8 | Pages: No page available

10.1111/petr.13597 | PMID 31657095 Get It

Abstract The NAPRTCS has collected clinical information on children undergoing renal transplantation since 1987 and now includes information on 12 920 renal transplants in 11 870 patients. Since the first data analysis in 1989, NAPRTCS reports have documented marked improvements in patient and allograft outcomes after pediatric renal transplantation in addition to identifying factors associated with both favorable and poor outcomes. The registry has served to document and influence practice patterns, clinical outcomes, and changing trends in renal transplantation and also provides historical perspective. This report highlights current practices in an era of major changes in DD kidney allocation and continuing steroid minimization. This report presents outcomes of the patients in the NAPRTCS transplant registry up to end of 2017. In particular, an increase in the cumulative incidence of late first AR has occurred in the most recent cohort, while all prior cohorts had a lower cumulative incidence of late first AR.
Impacts of smoke-free policies on 30-day readmission rates following hospitalization for chronic obstructive pulmonary disease in the United States
Peterson, Breck, Apatu, Emma , Stallings‐Smith, Sericea , Hamadi, Hanadi , Spaulding, Aaron

Mayo Clinic

Environmental Epidemiology | October 23, 2019 | Volume: 3 | Issue: Supplement 1 | Pages: 381-382

10.1097/01.ee9.0000610244.85951.7d Get It

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma
Chen, Robert W., Fenske, Timothy S. , Shea, Thomas C., Barr, Paul M. , Leonard, John P. , Friedberg, Jonathan W. , Smith, Sonali M. , Barr, Paul M , Kamdar, Manali , Li, Hongli , Rimsza, Lisa M. , LeBlanc, Michael , Phillips, Tycel , Kahl, Brad S.

Mayo Clinic

Blood Advances | October 22, 2019 | Volume: 3 | Issue: 20 | Pages: 3132-3135

10.1182/bloodadvances.2019000526 | PMID 31648328 Get It

Key Points Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.
Perioperative clinical pharmacy practice: Responsibilities and scope within the surgical care continuum
Patel, Gourang , Hyland, Sara J. , Birrer, Kara L., Lovely, Jenna K. , Smith, April N. , Dixon, Russell L., Johnson, Eric , Gaviola, Marian L. , Giancarelli, Amanda, Vincent, William R. , Richardson, Carole, Wolfe, Rachel C. , Richardson, Carole, Parrish, Richard H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | October 21, 2019 | Volume: 3 | Issue: 2 | Pages: 501-519

10.1002/jac5.1185 Get It

AbstractCurrent published guidelines for perioperative pharmacy services have limited information on the development and implementation of a robust clinical pharmacy program across the surgical continuum of care. This publication defines the responsibilities and scope of practice of the Perioperative Clinical Pharmacist (PCPh), supporting the PCPh as a critical member of the interprofessional surgical patient care team. Opportunities for pharmacist role integration into perioperative medication management processes are described along with published examples of successful PCPh practice models, including those with interventions targeted toward Enhanced Recovery Pathways (ERP). Recommended training and competencies for future and practicing perioperative pharmacists, in addition to considerations for precepting and scholarly activities, are also outlined. Finally, future developments in perioperative pharmacy practice are discussed, including technological advancements, improved predictive models, and expansion of collaborative practice agreements.
P851Incidence and prognostic impact of acute infection among patients with type 1 and 2 myocardial infarction
Sandoval, Yader , Schulz, Karen , Sexter, Anne, Apple, F S, Smith, Stephen W. , Apple, F S

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz747.0449 Get It

Abstract Background The incidence and impact of acute infection among patients with type 1 (T1MI) and 2 myocardial infarction (T2MI) is not well known. Inflammation and increased procoagulant activity can lead to T1MI, whereas cytokine release can cause hemodynamic alterations affecting myocardial oxygen consumption and contribute to T2MI. Purpose Determine the incidence and prognostic impact of acute infection among patients with T1MI and T2MI. Methods Post-hoc analysis of UTROPIA (NCT02060760), a prospective, observational cohort study involving 1,640 consecutive emergency department patients with serial cardiac troponin (cTn) I measurements obtained on clinical indication. The incidence of acute infection, antibiotic use, and/or laboratory evidence of infection were examined among patients with T1MI and T2MI. 5-year cumulative survival curves were plotted using the Kaplan-Meier method, frequencies were compared via Chi-Square, and a multivariate cox-proportional hazards model was used to assess the impact of infection on mortality. Results Among 217 patients with acute MI (T1MI, n=77 and T2MI, n=140), acute infection occurred in 63 (29%) of patients. Acute infection was more common in patients with T2MI than T1MI (35% vs. 18%, p=0.009). The predominant source of infection was pneumonia (59%), followed by urinary tract infections (11%). Patients with T2MI were also more likely than T1MI to have sepsis (11% vs. 1%, p=0.012), bacteremia (30% vs. 18%, p=0.057), and antibiotic use (35% vs. 17%, p=0.005). At 5-years, patients with acute MI and acute infection had a higher mortality rate than patients without infection (49% vs. 25%, p=0.0006) (Figure). Among the 31 deaths in MI patients with acute infection, most deaths were non-cardiac (65%) and occurred in those with T2MI (77%). Following adjustment for age, sex, and comorbidities in a Cox proportional hazards model, acute infection was an independent predictor of death (hazard ratio: 2.2, 95% CI: 1.3–3.5, p=0.0016). Conclusion Acute infection occurs in almost a third of patients that are diagnosed with acute MI during the index hospitalization. Most infections are due to pneumonia and occur most often in patients classified as having T2MI. Acute infection is an independent risk factor for 5-year mortality, with nearly half of all patients with acute MI in whom concomitant acute infection is present during the index hospitalization dead at 5-years. Most deaths are non-cardiac and the vast majority occur in patients with T2MI. Acknowledgement/Funding Abbott Diagnostics and Hennepin Healthcare Research Institute (formerly MMRF)e
P3608Long-term mortality and mode of death among patients with type 1 and 2 myocardial infarction
Sandoval, Yader , Schulz, Karen , Sexter, Anne, Apple, F S, Smith, Stephen W. , Apple, F S

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz745.0467 Get It

Abstract Background Few studies address long-term outcomes among patients with type 2 myocardial infarction (T2MI). It has been suggested that patients with T2MI with concomitant stable ischemic heart disease are at higher-risk. Purpose Our goals were two-fold. First, to examine 5-year mortality rates and mode of death among patients with type 1 (T1MI) and T2MI. Second, to evaluate the prognostic impact of coronary artery disease (CAD) on long-term outcomes among patients with T2MI. Methods Post-hoc analysis of UTROPIA (NCT02060760), a prospective, observational cohort study involving 1,640 consecutive emergency department patients with serial cardiac troponin (cTn) I measurements obtained on clinical indication. 5-year death rates, including mode of death, were examined among patients with T1MI and T2MI. CAD was defined as the presence of any of the following: history of CAD, prior MI, prior coronary artery bypass graft surgery, prior percutaneous coronary intervention, prior coronary stenting, or documented CAD (≥50%) on index admission angiography. Results Among 1640 patients, acute MI was diagnosed in 217 patients, including 77 (4.7%) classified as T1MI and 140 (8.5%) as T2MI. At 5-years, 23% (n=18) of patients with T1MI had died, with 61% (n=11) categorized as cardiac deaths. For T2MI, 37% (n=52) had died at 5-years, with 36% (n=19) categorized as cardiac deaths. Patients with T2MI had a higher 5-year mortality than T1MI (37% vs 23%, p=0.038) (Figure, Panel A), with T2MI more likely than T1MI to die from non-cardiac causes (64% vs. 39%, p=0.04). CAD was present in 22% (n=31) of patients with T2MI and associated with worse outcomes (p=0.0496) (Figure, Panel B). Conclusion T2MI has worse long term outcomes than T1MI. The predominant mode of death among patients with T2MI is non-cardiac. However, approximately 40% of deaths are cardiac. Further, we confirm the presence of CAD identifies a subset of patients with T2MI at high-risk. Acknowledgement/Funding Abbott Diagnostics and Hennepin Healthcare Research Institute (formerly MMRF)